10/15
First Tracks Biotherapeutics Announces Positive Top-Line Phase 1 Cohort 1 Results for Investigational Celiac Disease Treatment
On October 12th, 2026, First Tracks Biotherapeutics announced positive top-line results from Cohort 1 (gluten-challenge) of ANB033’s Phase 1b trial in celiac disease. ANB033 is an investigational injection given under the…